Simultaneous targeting of EGFR and mTOR inhibits the growth of colorectal carcinoma cells

Bo Li, Shuohui Gao, Feng Wei, Anita Bellail, Chunhai Hao, Tongjun Liu

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Epidermal growth factor receptor (EGFR) is highly expressed in colorectal carcinomas and, as a result, it leads to the activation of downstream mammalian target of rapamycin (mTOR) kinase pathways for cancer growth and progression. Clinical and preclinical studies, however, have shown that inhibition of epidermal growth factor receptor (EGFR) and mammalian target of rapamycin (mTOR) alone is not sufficient to treat colorectal carcinomas. In search of effective combination therapies, we show here that simultaneous targeting of EGFR with its inhibitor, erlotinib and mTOR with its inhibitor, rapamycin inhibits the phosphorylation and activation of downstream phosphatidylinositol 3-kinase (PI3K), Akt, mTOR and extracellular-signal-regulated kinase 1/2 (Erk1/2) pathways, resulting in the inhibition of cell cycle progression and the growth of both KRAS wild-type and mutated colorectal carcinoma cells. This study has demonstrated the principle that the combination of erlotinib and rapamycin may provide an effective therapy for colorectal carcinomas.

Original languageEnglish (US)
Pages (from-to)15-20
Number of pages6
JournalOncology Reports
Volume28
Issue number1
DOIs
StatePublished - Jul 1 2012
Externally publishedYes

Fingerprint

Sirolimus
Epidermal Growth Factor Receptor
Colorectal Neoplasms
Growth
Phosphatidylinositol 3-Kinase
Mitogen-Activated Protein Kinase 3
Mitogen-Activated Protein Kinase 1
Cell Cycle
Phosphotransferases
Phosphorylation
Therapeutics
Neoplasms

Keywords

  • Cell cycle
  • Colorectal carcinoma
  • Epidermal growth factor receptor
  • Mammalian target of rapamycin
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Simultaneous targeting of EGFR and mTOR inhibits the growth of colorectal carcinoma cells. / Li, Bo; Gao, Shuohui; Wei, Feng; Bellail, Anita; Hao, Chunhai; Liu, Tongjun.

In: Oncology Reports, Vol. 28, No. 1, 01.07.2012, p. 15-20.

Research output: Contribution to journalArticle

Li, Bo ; Gao, Shuohui ; Wei, Feng ; Bellail, Anita ; Hao, Chunhai ; Liu, Tongjun. / Simultaneous targeting of EGFR and mTOR inhibits the growth of colorectal carcinoma cells. In: Oncology Reports. 2012 ; Vol. 28, No. 1. pp. 15-20.
@article{34b05c37ef5b47779b277dae1802cb4f,
title = "Simultaneous targeting of EGFR and mTOR inhibits the growth of colorectal carcinoma cells",
abstract = "Epidermal growth factor receptor (EGFR) is highly expressed in colorectal carcinomas and, as a result, it leads to the activation of downstream mammalian target of rapamycin (mTOR) kinase pathways for cancer growth and progression. Clinical and preclinical studies, however, have shown that inhibition of epidermal growth factor receptor (EGFR) and mammalian target of rapamycin (mTOR) alone is not sufficient to treat colorectal carcinomas. In search of effective combination therapies, we show here that simultaneous targeting of EGFR with its inhibitor, erlotinib and mTOR with its inhibitor, rapamycin inhibits the phosphorylation and activation of downstream phosphatidylinositol 3-kinase (PI3K), Akt, mTOR and extracellular-signal-regulated kinase 1/2 (Erk1/2) pathways, resulting in the inhibition of cell cycle progression and the growth of both KRAS wild-type and mutated colorectal carcinoma cells. This study has demonstrated the principle that the combination of erlotinib and rapamycin may provide an effective therapy for colorectal carcinomas.",
keywords = "Cell cycle, Colorectal carcinoma, Epidermal growth factor receptor, Mammalian target of rapamycin, Targeted therapy",
author = "Bo Li and Shuohui Gao and Feng Wei and Anita Bellail and Chunhai Hao and Tongjun Liu",
year = "2012",
month = "7",
day = "1",
doi = "10.3892/or.2012.1786",
language = "English (US)",
volume = "28",
pages = "15--20",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "1",

}

TY - JOUR

T1 - Simultaneous targeting of EGFR and mTOR inhibits the growth of colorectal carcinoma cells

AU - Li, Bo

AU - Gao, Shuohui

AU - Wei, Feng

AU - Bellail, Anita

AU - Hao, Chunhai

AU - Liu, Tongjun

PY - 2012/7/1

Y1 - 2012/7/1

N2 - Epidermal growth factor receptor (EGFR) is highly expressed in colorectal carcinomas and, as a result, it leads to the activation of downstream mammalian target of rapamycin (mTOR) kinase pathways for cancer growth and progression. Clinical and preclinical studies, however, have shown that inhibition of epidermal growth factor receptor (EGFR) and mammalian target of rapamycin (mTOR) alone is not sufficient to treat colorectal carcinomas. In search of effective combination therapies, we show here that simultaneous targeting of EGFR with its inhibitor, erlotinib and mTOR with its inhibitor, rapamycin inhibits the phosphorylation and activation of downstream phosphatidylinositol 3-kinase (PI3K), Akt, mTOR and extracellular-signal-regulated kinase 1/2 (Erk1/2) pathways, resulting in the inhibition of cell cycle progression and the growth of both KRAS wild-type and mutated colorectal carcinoma cells. This study has demonstrated the principle that the combination of erlotinib and rapamycin may provide an effective therapy for colorectal carcinomas.

AB - Epidermal growth factor receptor (EGFR) is highly expressed in colorectal carcinomas and, as a result, it leads to the activation of downstream mammalian target of rapamycin (mTOR) kinase pathways for cancer growth and progression. Clinical and preclinical studies, however, have shown that inhibition of epidermal growth factor receptor (EGFR) and mammalian target of rapamycin (mTOR) alone is not sufficient to treat colorectal carcinomas. In search of effective combination therapies, we show here that simultaneous targeting of EGFR with its inhibitor, erlotinib and mTOR with its inhibitor, rapamycin inhibits the phosphorylation and activation of downstream phosphatidylinositol 3-kinase (PI3K), Akt, mTOR and extracellular-signal-regulated kinase 1/2 (Erk1/2) pathways, resulting in the inhibition of cell cycle progression and the growth of both KRAS wild-type and mutated colorectal carcinoma cells. This study has demonstrated the principle that the combination of erlotinib and rapamycin may provide an effective therapy for colorectal carcinomas.

KW - Cell cycle

KW - Colorectal carcinoma

KW - Epidermal growth factor receptor

KW - Mammalian target of rapamycin

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84861553131&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861553131&partnerID=8YFLogxK

U2 - 10.3892/or.2012.1786

DO - 10.3892/or.2012.1786

M3 - Article

VL - 28

SP - 15

EP - 20

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 1

ER -